Funded Startups in Framingham
Among the 12 most recent entries, the largest disclosed round is Ameresco’s $262M Post-IPO Debt on 2022-03-10, which dwarfs the next-largest disclosed amou…
Among the 12 most recent entries, the largest disclosed round is Ameresco’s $262M Post-IPO Debt on 2022-03-10, which dwarfs the next-largest disclosed amounts (Tortugas Neuroscience at $106M on 2026-04-21 and Variantyx at $36M on 2024-04-26). Most disclosed rounds cluster below $20M, including DetraPel’s $8M (2023-09-11), Raven360’s $8M (2022-08-04), Xenetic Biosciences’ $13M (2021-07-26), and Trilio’s $17M (2022-12-12).
The city is consistently listed as Framingham, Massachusetts in every row, but dates span a wide window: 2021-06-10 (Punchbowl) through 2026-05-07 (AstralQ). Sector-wise, biotechnology appears in 4 of the 12 companies (Tortugas Neuroscience, Olaris, Variantyx, Xenetic Biosciences), while information/consumer/economic-adjacent categories are each represented by single-digit counts. Stage labels are mixed: 3 entries are “undisclosed” by amount (AstralQ 2026-05-07, Olaris 2025-04-08, plus others not counted here), and 3 entries use “Series Unknown” (Variantyx, Bluespec, and Punchbowl’s row shows no stage label).
Most recent rounds
12 shownRelated listings
Frequently asked
What stands out most in disclosed deal sizes, and is it an outlier in Framingham?
Ameresco’s disclosed $262M Post-IPO Debt on 2022-03-10 is an outlier: the next-largest disclosed amount is Tortugas Neuroscience’s $106M on 2026-04-21, followed by Variantyx at $36M on 2024-04-26.
Are there recent-time clusters among the Framingham rounds shown?
Yes. Two biotechnology entries appear in close succession in 2026: Tortugas Neuroscience ($106M, Series A) on 2026-04-21 and AstralQ (Seed) on 2026-05-07, while the list also clusters mid-decade with Variantyx ($36M, Series Unknown) on 2024-04-26 and DetraPel ($8M, Series A) on 2023-09-11.
Which sectors are over-represented in this set of 12 Framingham companies?
Biotechnology is the only sector that repeats at meaningful frequency, appearing in 4 of 12 companies: Tortugas Neuroscience (2026-04-21, $106M), Olaris (2025-04-08, undisclosed), Variantyx (2024-04-26, $36M), and Xenetic Biosciences (2021-07-26, $13M).
How much of the list is hard to benchmark because the round amount or stage is missing?
Three entries show “undisclosed” amounts (AstralQ on 2026-05-07, Olaris on 2025-04-08, and the other “undisclosed” row in the listing), and three entries use “Series Unknown” or missing stage labels (Variantyx, Bluespec, and Punchbowl’s stage field is blank).
If the goal is pipeline qualification, what stage mix appears most often among disclosed rounds?
Among named rounds with disclosed amounts, “Series A/B” is a common pattern: DetraPel is Series A ($8M, 2023-09-11), Tortugas Neuroscience is Series A ($106M, 2026-04-21), Trilio is Series B ($17M, 2022-12-12), and Raven360 is Series B ($8M, 2022-08-04), while debt and equity outside traditional series also appear (Imagin Medical Post-IPO Debt at $7M on 2022-08-22 and Ameresco Post-IPO Debt at $262M on 2022-03-10).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.